SLGL — Sol-Gel Technologies Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1684693 ·
Israel
Last close
$52.83
Market Cap
$172.97M
52W High
$97.97
52W Low
$32.51
ADV30
37,887
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 41,000 | — | -6,105,000 | -5,622,000 | 50,202,000 | 13,094,000 | 7,392,000 |
| Jun 2026 | 591,000 | — | -4,162,000 | -3,681,000 | 53,756,000 | 16,662,000 | 5,660,000 |
| Mar 2026 | 108,000 | — | -3,855,000 | -3,727,000 | 58,550,000 | 10,136,000 | 7,144,000 |
| Dec 2025 | 696,000 | — | -3,411,000 | -2,987,000 | 29,917,000 | 11,033,000 | 7,106,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-244,418,000
Inventory
—
Receivables
$713,000
ST Investments
$31,267,000
EBIT TTM
$-17,716,000
Pretax Income TTM
$-16,337,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,795,000
EBITDA
$-17,690,000
Free Cash Flow
$-2,120,250
Enterprise Value
$168,728,496
Total Cash
$47,929,000
Total Debt
$770,000
Shares Out
3,273,999
Trailing EPS
$-5.62
Book Value
$14.69
ROE
-40.9%
ROA
-23.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 19,388,000 | -7,538,000 | -6,127,000 | 29,917,000 | 7,106,000 | 22,811,000 | 322,000 |
| Dec 2024 | 11,538,000 | -12,014,000 | -10,580,000 | 35,846,000 | 6,996,000 | 28,850,000 | -13,889,000 |
| Dec 2023 | 1,554,000 | -29,305,000 | -27,238,000 | 45,287,000 | 6,643,000 | 38,644,000 | -17,730,000 |
| Dec 2022 | 3,883,000 | -16,244,000 | -14,923,000 | 46,628,000 | 4,415,000 | 42,213,000 | -9,484,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-7.70
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | $172.24M | $1.44 | — |
| IFRX | InflaRx N.V. | $169.47M | $1.15 | — |
| KRRO | Korro Bio, Inc. | $169.10M | $12.32 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $168.29M | $3.87 | — |
| ELDN | Eledon Pharmaceuticals, Inc. | $167.23M | $1.98 | — |
News headlines (Yahoo Finance, 1h cache)
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 13:40 · Yahoo
Sol-Gel Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
2026-11-12 13:30 · Yahoo
Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data
2026-10-15 03:02 · Yahoo
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
2026-09-30 13:14 · Yahoo
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
2026-09-17 12:30 · Yahoo
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-20 12:30 · Yahoo
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
2026-10-29 22:05 · Yahoo
New Strong Buy Stocks for October 16th
2026-10-16 07:04 · Yahoo
SolGel Technologies (SLGL) Upgraded to Buy: Here's Why
2026-10-08 15:00 · Yahoo
SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-09-17 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.